Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

[Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper].

Augustin AJ, Feltgen N, Haritoglou C, Hoerauf H, Maier MM, Mardin CY, Schargus M.

Klin Monbl Augenheilkd. 2019 Nov 26. doi: 10.1055/a-1024-4089. [Epub ahead of print] German.

PMID:
31770786
2.

[Non-arteritic Anterior Ischaemic Optic Neuropathy: Pathogenesis and Therapeutic Approaches].

van Oterendorp C, Lagrèze WA, Feltgen N.

Klin Monbl Augenheilkd. 2019 Nov;236(11):1283-1291. doi: 10.1055/a-0972-1625. Epub 2019 Nov 11. German.

PMID:
31711249
3.

Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials.

Pielen A, Feltgen N, Hattenbach LO, Hoerauf H, Bertelmann T, Quiering C, Vögeler J, Priglinger S, Lang GE, Schmitz-Valckenberg S, Wolf A, Rehak M.

Curr Eye Res. 2019 Oct 31:1-11. doi: 10.1080/02713683.2019.1679839. [Epub ahead of print]

PMID:
31665935
4.

[Ophthalmological student teaching-results of a survey at German universities].

DOG-Arbeitskreis Lehre; Gruppe der ophthalmologischen Lehrbeauftragten Deutschland, Feltgen N.

Ophthalmologe. 2019 Oct 25. doi: 10.1007/s00347-019-00984-8. [Epub ahead of print] German.

PMID:
31654135
5.

Distance-Thresholded Intercapillary Area Analysis Versus Vessel-Based Approaches to Quantify Retinal Ischemia in OCTA.

Lauermann P, van Oterendorp C, Storch MW, Khattab MH, Feltgen N, Hoerauf H, Bemme S.

Transl Vis Sci Technol. 2019 Aug 19;8(4):28. doi: 10.1167/tvst.8.4.28. eCollection 2019 Jul.

6.

[Current importance of heavy fluids as intraoperative aids in vitreoretinal surgery].

Feltgen N, Hoerauf H.

Ophthalmologe. 2019 Oct;116(10):919-924. doi: 10.1007/s00347-019-0935-x. Review. German.

PMID:
31309273
7.

Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.

Feltgen N, Ogura Y, Boscia F, Holz FG, Korobelnik JF, Brown DM, Heier JS, Stemper B, Rittenhouse KD, Asmus F, Ahlers C, Vitti R, Saroj N, Mitchell P.

Ophthalmol Retina. 2019 Jul;3(7):553-560. doi: 10.1016/j.oret.2019.02.010. Epub 2019 Feb 27.

PMID:
31277796
8.

Hydrofluoric Acid and Other Impurities in Toxic Perfluorooctane Batches.

Menz DH, Feltgen N, Lechner T, Menz H, Müller BK, Dresp J, Hoerauf H.

Transl Vis Sci Technol. 2019 May 29;8(3):24. doi: 10.1167/tvst.8.3.24. eCollection 2019 May.

9.

Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions: results from the Gutenberg Retinal Vein Occlusion Study.

Ponto KA, Scharrer I, Binder H, Korb C, Rosner AK, Ehlers TO, Rieser N, Grübel NC, Rossmann H, Wild PS, Feltgen N, Pfeiffer N, Mirshahi A.

J Hypertens. 2019 Jul;37(7):1372-1383. doi: 10.1097/HJH.0000000000002057.

PMID:
31145709
10.

[Peri-/Postoperative Anti-Inflammatory Therapy in Vitreoretinal Interventions].

Feltgen N, Agostini H, Lommatzsch AP, Schaub F, Hoerauf H.

Klin Monbl Augenheilkd. 2019 May;236(5):662-666. doi: 10.1055/a-0874-2394. Epub 2019 May 16. German.

PMID:
31096285
11.

[Complications in sutured scleral fixation of artificial lens implantation].

Brandt L, Petersen J, Callizo J, Bemme S, Pfeiffer S, Hoerauf H, Feltgen N, van Oterendorp C.

Ophthalmologe. 2019 Dec;116(12):1200-1206. doi: 10.1007/s00347-019-0896-0. German.

PMID:
30997528
12.

[Work sampling in ophthalmological clinical studies. A multicenter field study].

Böhringer D, Goos D, Ach T, Feltgen N, Fleckenstein M, Kohnen T, Lorenz K, Pielen A, Spital G, Wilhelm B, Böhringer S, Reinhard T; Arbeitsgemeinschaft DOG – Klinische Studienzentren.

Ophthalmologe. 2019 Sep;116(9):872-878. doi: 10.1007/s00347-019-0851-0. German.

PMID:
30684005
13.

Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.

Callizo J, Atili A, Striebe NA, Bemme S, Feltgen N, Hoerauf H, Bertelmann T.

Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):913-920. doi: 10.1007/s00417-018-04223-9. Epub 2019 Jan 4.

PMID:
30610424
14.

[Does the micropulse laser have an effect on chronic CSC?]

Striebe NA, Feltgen N, Khattab MH, Spier L, Callizo J, Bemme S, Hoerauf H, van Oterendorp C.

Ophthalmologe. 2019 Sep;116(9):850-856. doi: 10.1007/s00347-018-0839-1. German.

PMID:
30578429
15.

How to Ward Off Retinal Toxicity of Perfluorooctane and Other Perfluorocarbon Liquids?

Menz DH, Feltgen N, Menz H, Müller BK, Lechner T, Dresp J, Hoerauf H.

Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):4841-4846. doi: 10.1167/iovs.18-24698.

PMID:
30347078
16.

[Retinal manifestation in hematological diseases].

Rehak M, Feltgen N, Meier P, Wiedemann P.

Ophthalmologe. 2018 Sep;115(9):799-812. doi: 10.1007/s00347-018-0736-7. German.

PMID:
29881877
17.

Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.

Feltgen N, Hattenbach LO, Bertelmann T, Callizo J, Rehak M, Wolf A, Berk H, Eter N, Lang GE, Pielen A, Schmitz-Valckenberg S, Quiering C, Rose U, Hoerauf H; COMRADE Study Group.

Acta Ophthalmol. 2018 Dec;96(8):e933-e941. doi: 10.1111/aos.13770. Epub 2018 May 31.

18.

Intravenous thrombolysis in acute central retinal artery occlusion - A prospective interventional case series.

Schultheiss M, Härtig F, Spitzer MS, Feltgen N, Spitzer B, Hüsing J, Rupp A, Ziemann U, Bartz-Schmidt KU, Poli S.

PLoS One. 2018 May 29;13(5):e0198114. doi: 10.1371/journal.pone.0198114. eCollection 2018.

19.

[Management of anticoagulants in ophthalmic surgery-a survey among ophthalmic surgeons in Germany].

Feltgen N, Mele B, Dietlein T, Erb C, Eckstein A, Hager A, Heiligenhaus A, Helbig H, Hoerauf H, Hoffmann E, Pauleikhoff D, Schittkowski M, Seitz B, Sucker C, Suffo S, Schaudig U, Tost F, Thurau S, Walter P, Koscielny J.

Ophthalmologe. 2018 Jul;115(7):585-591. doi: 10.1007/s00347-018-0732-y. German.

PMID:
29770858
20.

[Oral anticoagulation : Current overview and perioperative management in ophthalmic surgery].

Sucker C, Hager A, Koscielny J, Feltgen N.

Ophthalmologe. 2019 Feb;116(2):144-151. doi: 10.1007/s00347-018-0724-y. Review. German.

PMID:
29766263
21.

Unilateral Vision Loss after a Dental Visit.

Khattab MH, Wiegand A, Storch M, Hoerauf H, Feltgen N.

Case Rep Ophthalmol. 2018 Mar 14;9(1):204-209. doi: 10.1159/000487586. eCollection 2018 Jan-Apr.

22.

[Increasing lipid exudation and vascular alterations associated with a choroidal nevus].

Lauermann P, Feltgen N, Khattab M, Storch M, Hoerauf H.

Ophthalmologe. 2018 Dec;115(12):1066-1069. doi: 10.1007/s00347-018-0652-x. German. No abstract available.

PMID:
29368017
23.

Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study.

Paul C, Heun C, Müller HH, Hoerauf H, Feltgen N, Wachtlin J, Kaymak H, Mennel S, Koss MJ, Fauser S, Maier MM, Schumann RG, Mueller S, Chang P, Schmitz-Valckenberg S, Kazerounian S, Szurman P, Lommatzsch A, Bertelmann T.

Br J Ophthalmol. 2018 Aug;102(8):1092-1097. doi: 10.1136/bjophthalmol-2017-310874. Epub 2017 Oct 31.

PMID:
29089354
24.

Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.

Staurenghi G, Feltgen N, Arnold JJ, Katz TA, Metzig C, Lu C, Holz FG; VIVID-DME and VISTA-DME study investigators.

Br J Ophthalmol. 2018 Jul;102(7):954-958. doi: 10.1136/bjophthalmol-2017-310664. Epub 2017 Oct 19.

25.

Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy.

Callizo J, Feltgen N, Ammermann A, Ganser J, Bemme S, Bertelmann T, Pfeiffer S, Duvinage A, Gröschel K, Hoerauf H, Wachter R.

PLoS One. 2017 Aug 3;12(8):e0181766. doi: 10.1371/journal.pone.0181766. eCollection 2017.

26.

[Retinal Vascular Occlusion: Modern Therapeutic Approaches].

Pettenkofer M, Feltgen N, Feucht N, Lohmann CP, Maier MM.

Klin Monbl Augenheilkd. 2018 Jul;235(7):830-839. doi: 10.1055/s-0043-106302. Epub 2017 Jul 27. Review. German.

PMID:
28750436
27.

[Treatment of Retinal Vein Occlusion - Is There Still a Role for Vitreoretinal Surgery?]

Feltgen N, Hansen LL, Agostini H.

Klin Monbl Augenheilkd. 2017 Sep;234(9):1103-1108. doi: 10.1055/s-0043-111801. Epub 2017 Jul 6. Review. German.

PMID:
28683483
28.

[Ultra-widefield angiography for retinal vein occlusion : How large is large enough?]

Storch M, Bemme S, Rehak M, Hoerauf H, Feltgen N.

Ophthalmologe. 2018 Jun;115(6):499-504. doi: 10.1007/s00347-017-0513-z. German.

PMID:
28560468
29.

Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy.

Bertelmann T, Frank HU, Fuchs HA, Feltgen N.

Case Rep Ophthalmol. 2017 Apr 28;8(1):271-278. doi: 10.1159/000475520. eCollection 2017 Jan-Apr.

30.

Risk of progression in macula-on rhegmatogenous retinal detachment.

Callizo J, Pfeiffer S, Lahme E, van Oterendorp C, Khattab M, Bemme S, Kulanga M, Hoerauf H, Feltgen N.

Graefes Arch Clin Exp Ophthalmol. 2017 Aug;255(8):1559-1564. doi: 10.1007/s00417-017-3696-8. Epub 2017 May 27.

PMID:
28551879
31.

[Prognosis and treatment of macular bleeding in neovascular age-related macular degeneration].

Agostini HT, Bopp S, Feltgen N.

Ophthalmologe. 2017 May;114(5):476-480. doi: 10.1007/s00347-017-0487-x. Review. German.

PMID:
28405758
32.

Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).

Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A, Weiss C, Paulus EM, Pielen A, Hoerauf H; COMRADE-B Study Group.

Acta Ophthalmol. 2018 Feb;96(1):e10-e18. doi: 10.1111/aos.13381. Epub 2017 Mar 2.

33.

[Erratum to: Retinal artery occlusion].

Feltgen N, Pielen A.

Ophthalmologe. 2017 Mar;114(3):236. doi: 10.1007/s00347-017-0479-x. German. No abstract available.

PMID:
28239776
34.

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Szurman GB, Meyer CH, Feltgen N, Pielen A, Spitzer B, Rehak M, Spital G, Dimopoulos S, Szurman P; Bevacizumab Study Group Venous Occlusion, Januschowski K.

Graefes Arch Clin Exp Ophthalmol. 2017 May;255(5):1045-1046. doi: 10.1007/s00417-017-3618-9. Epub 2017 Feb 21. No abstract available.

PMID:
28224287
35.

Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.

Ziemssen F, Feltgen N, Holz FG, Guthoff R, Ringwald A, Bertelmann T, Wiedon A, Korb C; OCEAN study group.

BMC Ophthalmol. 2017 Jan 19;17(1):7. doi: 10.1186/s12886-017-0401-y.

36.

Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.

Feltgen N, Bertelmann T, Bretag M, Pfeiffer S, Hilgers R, Callizo J, Goldammer L, Bemme S, Hoerauf H.

Graefes Arch Clin Exp Ophthalmol. 2017 May;255(5):923-934. doi: 10.1007/s00417-017-3589-x. Epub 2017 Jan 19.

PMID:
28102456
37.

[Retinal artery occlusion].

Feltgen N, Pielen A.

Ophthalmologe. 2017 Feb;114(2):177-190. doi: 10.1007/s00347-016-0432-4. Review. German. Erratum in: Ophthalmologe. 2017 Mar;114(3):236.

PMID:
28093631
38.

[Buckling Surgery: Old Fashioned or Cutting Edge?]

Feltgen N, Hoerauf H.

Klin Monbl Augenheilkd. 2018 Feb;235(2):196-201. doi: 10.1055/s-0042-119299. Epub 2017 Jan 13. Review. German.

PMID:
28086252
39.

[Arch-shaped retinal appearance of a previously healthy women].

Khattab M, Feltgen N, Bemme S, Hoerauf H, Storch M.

Ophthalmologe. 2017 Jul;114(7):656-660. doi: 10.1007/s00347-016-0417-3. German. No abstract available.

PMID:
27966033
40.

Erratum to: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Eter N, Mohr A, Wachtlin J, Feltgen N, Shirlaw A, Leaback R; German Ozurdex in RVO Real World Study Group.

Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):89. doi: 10.1007/s00417-016-3568-7. No abstract available.

41.

Reply to a letter to the editor: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Eter N, Mohr A, Wachtlin J, Feltgen N.

Graefes Arch Clin Exp Ophthalmol. 2017 Feb;255(2):429-430. doi: 10.1007/s00417-016-3560-2. Epub 2016 Dec 13. No abstract available.

PMID:
27957601
42.

IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY.

Paul C, Heun C, Müller HH, Fauser S, Kaymak H, Kazerounian S, Sekundo W, Mennel S, Meyer CH, Schmitz-Valckenberg S, Koss MJ, Feltgen N, Bertelmann T.

Retina. 2017 Jul;37(7):1252-1260. doi: 10.1097/IAE.0000000000001371.

PMID:
27787446
43.

[Platelet aggregation inhibitors and anticoagulants during ophthalmic interventions].

Feltgen N, Hoerauf H, Noske W, Hager A, Koscielny J.

Ophthalmologe. 2016 Dec;113(12):1010-1022. Review. German.

PMID:
27671998
44.

Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.

Bertelmann T, Feltgen N, Scheffler M, Hufenbach U, Wiedon A, Wilhelm H, Ziemssen F.

Health Qual Life Outcomes. 2016 Sep 20;14(1):132. doi: 10.1186/s12955-016-0536-1.

45.

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Januschowski K, Feltgen N, Pielen A, Spitzer B, Rehak M, Spital G, Dimopoulos S; Bevacizumab Study Group Venous Occlusion, Meyer CH, Szurman GB.

Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):457-462. doi: 10.1007/s00417-016-3471-2. Epub 2016 Sep 8.

PMID:
27632214
46.

[Optic disc pit-associated maculopathy and iris-retinochoroidal-coloboma - a rare combination].

Storch M, Feltgen N, Hoerauf H.

Ophthalmologe. 2017 Jul;114(7):646-649. doi: 10.1007/s00347-016-0340-7. German.

PMID:
27514522
47.

Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.

Eter N, Mohr A, Wachtlin J, Feltgen N, Shirlaw A, Leaback R; German Ozurdex in RVO Real World Study Group.

Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):77-87. doi: 10.1007/s00417-016-3431-x. Epub 2016 Jul 26. Erratum in: Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255 (1):89.

48.

Reply.

Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO.

Am J Ophthalmol. 2016 Sep;169:292-293. doi: 10.1016/j.ajo.2016.06.016. Epub 2016 Jul 9. No abstract available.

PMID:
27401725
49.

Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.

Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO; COMRADE-C Study Group.

Am J Ophthalmol. 2016 Sep;169:258-267. doi: 10.1016/j.ajo.2016.04.020. Epub 2016 May 7.

PMID:
27163237
50.

Gefäßverschlüsse.

Feltgen N.

Ophthalmologe. 2016 Apr;113(4):278-9. doi: 10.1007/s00347-016-0253-5. German. No abstract available.

PMID:
27083172

Supplemental Content

Loading ...
Support Center